AbbVie Inc. reported its financial results for the second quarter of 2025, showcasing a strong performance with worldwide net revenues reaching $15.423 billion, marking an increase of 6.6 percent on a reported basis. The company's immunology portfolio contributed significantly to this growth, with global net revenues totaling $7.631 billion, up by 9.5 percent. Among the notable products, Skyrizi achieved global net revenues of $4.423 billion, representing a significant rise of 62.2 percent. Rinvoq also demonstrated impressive growth with global net revenues of $2.028 billion, an increase of 41.8 percent. In contrast, Humira's global net revenues decreased by 58.1 percent, amounting to $1.180 billion. AbbVie reported a second-quarter diluted EPS of $0.52 on a GAAP basis, while the adjusted diluted EPS was $2.97, reflecting a 12.1 percent increase. These results were impacted by a $0.42 per share expense related to acquired IPR&D and milestones. Looking ahead, AbbVie has raised its 2025 adjusted diluted EPS guidance range from $11.67 - $11.87 to $11.88 - $12.08, despite the unfavorable impact of $0.55 per share from acquired IPR&D and milestones expense incurred year-to-date through the second quarter. The company continues to advance with regulatory approvals, positive clinical data, and strategic investments in external innovation, providing momentum as it enters the second half of the year.